VTRS Aug 2024 10.000 call
| Previous close | 0.7700 |
| Open | 0.7500 |
| Bid | 0.6500 |
| Ask | 0.8000 |
| Strike | 10.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireViatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures.
- PR Newswire
U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
ZacksHere's Why You May Invest in Theravance (TBPH) Stock Now
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
